AU550007B2 - Complex of 4-hydroxy-2-methyl-n-2-pyridyl-2h-1, 2-benzothiazine-3-carboxamide-1, 1-dioxide and alpha, beta, gamma-type cyclodextrin - Google Patents

Complex of 4-hydroxy-2-methyl-n-2-pyridyl-2h-1, 2-benzothiazine-3-carboxamide-1, 1-dioxide and alpha, beta, gamma-type cyclodextrin

Info

Publication number
AU550007B2
AU550007B2 AU38923/85A AU3892385A AU550007B2 AU 550007 B2 AU550007 B2 AU 550007B2 AU 38923/85 A AU38923/85 A AU 38923/85A AU 3892385 A AU3892385 A AU 3892385A AU 550007 B2 AU550007 B2 AU 550007B2
Authority
AU
Australia
Prior art keywords
benzothiazine
hydroxy
dioxide
methyl
pyridyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU38923/85A
Other languages
English (en)
Other versions
AU3892385A (en
Inventor
Paolo Chiesi
Vittorio Servadio
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chiesi Farmaceutici SpA
Original Assignee
Chiesi Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farmaceutici SpA filed Critical Chiesi Farmaceutici SpA
Publication of AU3892385A publication Critical patent/AU3892385A/en
Application granted granted Critical
Publication of AU550007B2 publication Critical patent/AU550007B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nanotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
AU38923/85A 1984-02-22 1985-02-18 Complex of 4-hydroxy-2-methyl-n-2-pyridyl-2h-1, 2-benzothiazine-3-carboxamide-1, 1-dioxide and alpha, beta, gamma-type cyclodextrin Expired AU550007B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT19735/84A IT1196033B (it) 1984-02-22 1984-02-22 Composto ad attivita' antiinfiammatoria ottenuto per complessazione con beta-ciclodestrina e relative formulazioni farmaceutiche
IT19735/84 1984-02-22

Publications (2)

Publication Number Publication Date
AU3892385A AU3892385A (en) 1985-08-29
AU550007B2 true AU550007B2 (en) 1986-02-27

Family

ID=11160778

Family Applications (1)

Application Number Title Priority Date Filing Date
AU38923/85A Expired AU550007B2 (en) 1984-02-22 1985-02-18 Complex of 4-hydroxy-2-methyl-n-2-pyridyl-2h-1, 2-benzothiazine-3-carboxamide-1, 1-dioxide and alpha, beta, gamma-type cyclodextrin

Country Status (19)

Country Link
US (1) US4603123A (enExample)
EP (1) EP0153998B1 (enExample)
JP (1) JPS60208979A (enExample)
KR (1) KR870001960B1 (enExample)
AT (1) ATE52263T1 (enExample)
AU (1) AU550007B2 (enExample)
BE (1) BE900836A (enExample)
CA (1) CA1234106A (enExample)
DE (2) DE3482041D1 (enExample)
DK (1) DK164911C (enExample)
ES (1) ES536909A0 (enExample)
IE (1) IE58231B1 (enExample)
IT (1) IT1196033B (enExample)
MY (1) MY101374A (enExample)
NZ (1) NZ211114A (enExample)
PH (1) PH22075A (enExample)
PT (1) PT79997B (enExample)
SG (1) SG53690G (enExample)
ZA (1) ZA848156B (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU43290B (en) * 1986-11-13 1989-06-30 Lek Tovarna Farmacevtskih Process for preparing inclusioned complex of ibuproxane with beta-cyclodextrine
IT1204725B (it) * 1987-06-17 1989-03-10 Edmond Pharma Srl Complessi di inclusione del dipiridamolo con ciclodestrine
NZ225045A (en) * 1987-07-01 1990-06-26 Janssen Pharmaceutica Nv Antiviral pharmaceutical compositions containing cyclodextrin and an antiviral agent
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US5017566A (en) * 1987-12-30 1991-05-21 University Of Florida Redox systems for brain-targeted drug delivery
DE3809808A1 (de) * 1988-03-23 1989-10-05 Hexal Pharma Gmbh & Co Kg Feste, insbesondere festorale und rektale, etofenamat enthaltende arzneimittel
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
IT1241088B (it) * 1990-03-27 1993-12-29 Chiesi Farma Spa Procedimento per la preparazione di complessi piroxicam/ciclodestrina,prodotti ottenuti e loro composizioni farmaceutiche
US5180716A (en) * 1990-08-01 1993-01-19 The Regents Of The University Of California Cyclodextrin complexes for neuraxial administration of drugs
EP0519428B1 (en) * 1991-06-21 2000-09-20 Takeda Chemical Industries, Ltd. Cyclodextrin compositions with fumagillol derivates
US20040014695A1 (en) * 1992-06-19 2004-01-22 Supergen, Inc. Pharmaceutical formulation
US5602112A (en) 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
IL111184A (en) * 1993-10-08 2000-08-13 Farmarc Nederland B V Of Cito Crystalline inclusion complex of diclofenac with unsubstituted beta-cyclodextrin
US5646131A (en) * 1994-02-22 1997-07-08 The Arab Company For Drug Industries And Medical Applicances (Acdima) Method for solubilizing drugs using cyclodextrins and carboxylic acids
IT1269578B (it) * 1994-04-22 1997-04-08 Chiesi Farma Spa Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo acido, una ciclodestrina e una base.
ZA959469B (en) * 1994-11-15 1996-05-15 South African Druggists Ltd Pharmaceutical composition
US5824668A (en) * 1996-11-07 1998-10-20 Supergen, Inc. Formulation for administration of steroid compounds
UA57734C2 (uk) 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
US6667056B2 (en) * 1997-07-23 2003-12-23 Chiesi Farmaceutici S.P.A. Pharmaceutical compositions containing an effervescent acid-base couple
IT1293764B1 (it) * 1997-07-23 1999-03-10 Chiesi Farma Spa Composizioni farmaceutiche sotto forma di compresse effervescenti contenenti un principio attivo instabile in presenza di acqua
FR2786395A1 (fr) * 1998-12-01 2000-06-02 Virbac Sa Compositions seches solubles en presence d'eau et evitant la reaction de maillard a l'etat sec, leur preparation et leurs applications
TWI242015B (en) 1999-11-29 2005-10-21 Akzo Nobel Nv 6-mercapto-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block
AU2002241611A1 (en) * 2000-12-04 2002-06-18 Sepracor, Inc. Orally-bioavailable formulations of fentanyl and congeners thereof
GB0205253D0 (en) * 2002-03-06 2002-04-17 Univ Gent Immediate release pharmaceutical granule compositions and a continuous process for making them
DE60219609T2 (de) * 2002-06-17 2008-01-03 Chiesi Farmaceutici S.P.A. Prozess für die Vorbereitung von Piroxicam: Beta-Cyclodextrin Einschlusskomplexe
EP1582221A1 (en) * 2004-03-31 2005-10-05 Chiesi S.A. Pharmaceutical oral compositions with a taste masking effect
JP5091661B2 (ja) 2004-04-01 2012-12-05 ピエール ファーブル メディカモン 超臨界ｃｏ２と錯体相互作用剤を用いる方法によって得られる包接錯体
DE502004002443D1 (de) * 2004-04-15 2007-02-08 Helm Ag Verfahren zur Herstellung von freifliessenden, pulverförmigen Valsartan-Adsorbaten
US20060024922A1 (en) * 2004-07-27 2006-02-02 Da-Tung Wen Method for cutting wafer
AU2005268972A1 (en) * 2004-08-02 2006-02-09 Chiesi Farmaceutici S.P.A. A process for the preparation of a piroxicam: beta­cyclodextrin inclusion compound
FR2876910B1 (fr) 2004-10-21 2007-04-13 Pierre Fabre Medicament Sa Complexe comprenant la mequitazine, une cyclodextrine et un agent d'interaction
US20070009532A1 (en) * 2005-07-06 2007-01-11 Branimir Sikic Treatment of patients with cancer using a calicheamicin-antibody conjugate in combination with zosuquidar
US20070010487A1 (en) * 2005-07-06 2007-01-11 Jeff Schwegman Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
US20070010465A1 (en) * 2005-07-06 2007-01-11 Branimir Sikic Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer
US20070010486A1 (en) * 2005-07-06 2007-01-11 Jeff Schwegman Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
US20070010485A1 (en) * 2005-07-06 2007-01-11 Jeff Schwegman Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
GB0612695D0 (en) * 2006-06-27 2006-08-09 Univ Gent Process for preparing a solid dosage form
CL2007003876A1 (es) * 2007-12-28 2008-03-07 Univ De Concepcion Y Lab Andro Complejo de inclusion que esta formado por disulfiram y ciclodextrina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de la dependencia de alcohol y cocaina.
KR101383941B1 (ko) * 2012-03-09 2014-04-10 동아에스티 주식회사 피록시캄 또는 약제학적으로 허용되는 그의 염과 히알루론산 또는 약제학적으로 허용되는 그의 염의 안정한 액상 조성물 및 그 제조방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2827452A (en) * 1955-05-31 1958-03-18 Univ Minnesota Stabilization of materials
US3969338A (en) * 1971-03-15 1976-07-13 Institut National De La Recherche Agronomique Protein obtained from cakes of vegetable origin
HU184066B (en) * 1979-12-28 1984-06-28 Chinoin Gyogyszer Es Vegyeszet Plant growth regulating substance and process for preparing such compound
HU182217B (en) * 1980-10-17 1983-12-28 Chinoin Gyogyszer Es Vegyeszet Process for producing inclusive complexes of cyclodextrines and strong inorganic oxyacids
JPS5838250A (ja) * 1981-09-01 1983-03-05 Teikoku Chem Ind Corp Ltd 複合体
JPS58126810A (ja) * 1981-12-24 1983-07-28 Kaken Pharmaceut Co Ltd 抗炎症眼科用液剤およびその製法
JPS5920230A (ja) * 1982-07-19 1984-02-01 チバ−ガイギ−・アクチエンゲゼルシヤフト ピルプロフエン含有薬剤

Also Published As

Publication number Publication date
DK76085A (da) 1985-08-23
DK164911B (da) 1992-09-07
US4603123A (en) 1986-07-29
ES8504789A1 (es) 1985-05-01
ATE52263T1 (de) 1990-05-15
JPS60208979A (ja) 1985-10-21
DK164911C (da) 1993-01-18
IE850325L (en) 1985-08-22
BE900836A (fr) 1985-02-15
PH22075A (en) 1988-05-20
ES536909A0 (es) 1985-05-01
JPH0370705B2 (enExample) 1991-11-08
IT1196033B (it) 1988-11-10
DE153998T1 (de) 1986-04-10
DE3482041D1 (de) 1990-05-31
EP0153998A3 (en) 1987-01-14
NZ211114A (en) 1987-09-30
SG53690G (en) 1990-11-23
EP0153998B1 (en) 1990-04-25
ZA848156B (en) 1985-06-26
PT79997A (en) 1985-03-01
IT8419735A0 (it) 1984-02-22
KR870001960B1 (ko) 1987-10-23
KR850006133A (ko) 1985-10-02
AU3892385A (en) 1985-08-29
CA1234106A (en) 1988-03-15
MY101374A (en) 1991-10-23
EP0153998A2 (en) 1985-09-11
PT79997B (en) 1987-01-13
DK76085D0 (da) 1985-02-19
IE58231B1 (en) 1993-08-11

Similar Documents

Publication Publication Date Title
AU550007B2 (en) Complex of 4-hydroxy-2-methyl-n-2-pyridyl-2h-1, 2-benzothiazine-3-carboxamide-1, 1-dioxide and alpha, beta, gamma-type cyclodextrin
BR9714777A (pt) Composto de indenonaftopiranos e artigo fotocrÈmico
ES2058725T3 (es) Aplicacion transdermica de 2-amino-6-n-propilamino-4,5,6,7-tetrahidrobenzotiazol.
BR9405351A (pt) Ação combinada de endoglucanases e celobioidrolases
AU5715294A (en) Use of 2-amino-6-A-propylamino-4,5,6, 7-tetrahydrobenzothiazole (pramipexol) as an anti-depressantdrug
DE69635275D1 (de) Stabilisierte wässerige steroidimmunteststandarten mit cyclodextrins
AU2979789A (en) Gas-phase reaction of 1,1,1-trifluorochloroethane with hydrogen fluoride to produce 1,1,1,2-tetrafluoroethane
DE69217911D1 (de) Schwefelfarbstoffzubereitungen sowie ihre herstellung
DE3577433D1 (de) Herstellung optisch aktiver 1,3-dioxolan-4-methanol-verbindungen.
EP0181166A3 (en) Solubilised platinum compounds
ES8303339A1 (es) Un procedimiento para la preparacion de 2,3-dicloro-5-triclorometilpiridina.
EP0369678A3 (en) Bleach composition
USD287979S (en) Font of type
AU570552B2 (en) 1,4-dihydropyridine-3-carboxylates and salts thereof
ES8700652A1 (es) Un metodo de preparar n-4-(3-aminopropil)-aminobutil-2,2-di-hidroxietanoamida
DE3886225D1 (de) Pyruvat-Oxidase, ihre Herstellung und Verwendung.
ES509901A0 (es) "digestor para la fermentacion celulosica, para la produccion de metano por fermentacion anaerobia".
USD286645S (en) Font of type
ZA848194B (en) Perfumery compounds and their preparations
ES2063279T3 (es) Heteropolisacarido 105-4.
AU4147685A (en) Fenoldopam 4', 8-bis-hydrogen sulfates
EP0109818A3 (en) Process for the preparation of penicillin and cephalosporin sulfones
SU1614519A1 (ru) Износостойкое покрытие режущего инструмента
DE3465071D1 (en) Process for the preparation of especially pharmacologically active compounds containing a sulfoxide group
MX9301360A (es) Procedimiento para preparar fenilglioxales substituidos y no substituidos a partir de acetofenonas substituidas y no substitudas correspondientes.